Evidence Synthesis & Translation for Real World Action
ESTRA brings the right experts, policymakers, and investors into the same room around longevity's hardest implementation problems — and stays until the solution is real. Singapore-based. Asia-European corridor.
What ESTRA does
Most institutions stop at the insight. ESTRA structures the conversation so the people who need to implement the answer are in the room building it. The debate is the implementation process.
Arena
The right people resolve longevity's most contested questions — not academically, but practically. Every Arena ends with public institutional commitments. ESTRA tracks whether they are kept.
QuarterlySignal
ESTRA collects and synthesises evidence into structured intelligence briefs. Cost modelling, evidence reviews, readiness assessments. What the data actually shows — clearly stated.
OngoingInsight
One precise question put to five to six verified experts. 350 words each. Collected independently, published simultaneously. ESTRA synthesises where the field agrees, where it diverges, and what that reveals.
MonthlyImplementation Lab
Eight to ten people. A specific problem. A structured process and a 10-page implementation blueprint an institution can actually use. ESTRA facilitates and retains the methodology as a reusable protocol.
Rolling cohortsFounding Project
ESTRA's founding project maps the evidence for longevity prevention across the world's major ageing economies — identifying where the science is strongest, calculating what inaction costs governments in real fiscal terms, and naming precisely what is stopping health systems from acting. Not as a report. As the basis for implementation.
Sub-projects by geography
Taiwan
Sub-Project 01
Super-aged society, universal single payer, 70B+ health records. The sharpest case for precision health as industrial strategy. NCD cost modelling using NHIRD published data. Arena I live.
Singapore
Sub-Project 02
National longevity strategy already embedded in government policy. ESTRA's home base. Prevention readiness assessment and implementation pilot design with MOH.
Central Europe
Sub-Project 03
Austria, Czechia, Slovakia — rapidly ageing EU member states with fragmented prevention systems. CEIAS corridor. Comparative analysis with Asian single-payer models.
Japan
Sub-Project 04
The world's oldest society. Tokutei Kenshin metabolic screening model — the most advanced preventive health system in Asia-Pacific. What worked and what it cost.
South Korea
Sub-Project 05
Fastest-ageing OECD country. National health screening programme with strong data infrastructure. Digital health integration and industrial precision health development.
Cross-system synthesis
Flagship Report
The ESTRA Global Prevention Dividend — a comparative analysis across all sub-projects. What the evidence shows at scale. The universal bottlenecks. The implementation pathways that actually transfer.
Sub-Project 01 — Active
Taiwan is simultaneously a super-aged society, a universal single-payer system, and a globally competitive advanced manufacturing base. ESTRA's first sub-project asks: what does existing NHIRD data tell us about the cost of not acting on prevention — and exactly where is the system stuck?
20%
Population aged 65+ — super-aged society since January 2026
99.9%
NHI coverage — single payer, universal access
70B+
Health records in NHIRD — decades of longitudinal linkage
NT$1.5M
NHI cost per dialysis patient per year — world's highest rate
The argument
Taiwan's demographic transition is not only a fiscal burden — it is a structural condition enabling a precision health industrial strategy. NCD demand generates data. Data supports analysis. Industrial capacity enables scaling.
What ESTRA is building
A structured cost modelling table across five NCD conditions: current NHI cost, prevention cost per person, estimated saving, payback period, and the specific implementation bottleneck in each case. Numbers a health ministry can hand to a budget committee.
Priority conditions
Hypertension — fastest measurable results, clearest stroke cost saving. Pre-diabetes — 58% progression reduction in landmark trials. CKD — highest per-patient NHI cost. Sarcopenia — fastest-growing long-term care driver. Cardiovascular disease — leading preventable hospitalisation cause.
Output and timeline
Signal 01 brief · NCD cost modelling table · Arena I synthesis · Implementation Lab protocol. All published open access. Arena I — Sep 2025. Full Signal report — Q4 2025.
Arena I — Live
The Arena is where ESTRA brings the right people into the same room around a specific contested question. Not to debate for its own sake — to produce commitments that can be tracked and implementation designs that can be tested.
NHI Policy Specialist
Former NHI Administration · Taiwan
Health Economist
NHIRD outcomes research · National Taiwan University
Primary Care Physician
Practicing clinician · Kaohsiung Medical University Hospital
Comparative Systems Expert
Asia-Pacific health systems · NUS Healthy Longevity
Data Governance Specialist
Health data policy · Central Europe
Position open
MedTech / industry perspective
Apply to contribute →
Signal
Signal is ESTRA's own data collection and analysis function. We gather, verify, and synthesise the evidence — producing structured intelligence briefs, cost models, and readiness assessments that are clear about what is known, what is uncertain, and what that means for a specific decision.
"Taiwan NCD Prevention Dividend — cost modelling using NHIRD published data across five priority conditions"
Signal 01 · In progressWhat Signal produces
Signal briefs are not reports for their own sake. Each one is designed to answer a question a decision-maker actually needs answered — with an explicit confidence rating, an explicit statement of what would change the conclusion, and a clear so-what for the institution reading it.
Insight
Insight is what happens when ESTRA puts one precise question to five to six verified experts. Their positions are submitted independently, published simultaneously, and synthesised by ESTRA into a citable intelligence product. What the field agrees on. Where it genuinely diverges. What that divergence reveals about the state of knowledge.
"What is the single biggest regulatory bottleneck preventing longevity biomarkers from entering clinical use in Asia-Pacific markets?"
Insight IHow to contribute an Insight
Contributing to an ESTRA Insight takes 90 minutes and produces a permanent citable record on an institutional platform alongside credible peers. ESTRA invites contributors on the basis of verified credentials and direct relevance to the question.
Living Registry
Every institutional commitment made in an ESTRA Arena, every Lab outcome, every Signal finding, every Insight synthesis — publicly recorded and followed up. Nothing disappears. Nothing is quietly abandoned.
"Initiate internal review of NHI reimbursement pathway for pre-diabetic structured intervention by Q4 2025"
NHI Administration, Taiwan
Arena I · Sep 2025
In progressSignal 01 — Taiwan NCD Prevention Dividend cost modelling
ESTRA · Taiwan Sub-Project
Q4 2025
In progressInsight I — Biomarker regulatory bottleneck synthesis published
ESTRA · Insight Series
Aug 2025
CompleteImplementation Lab I — Hypertension adherence protocol for primary care
ESTRA + KMUH, Taiwan
Nov 2025
FormingJoin ESTRA
For experts & researchers
ESTRA invites verified experts — clinicians, health economists, policy researchers, regulators, and technologists — to contribute Insights, join Arena debates, and participate in Implementation Labs. Your work reaches the people who can act on it.
For institutions & partners
Governments, health ministries, insurers, research institutions, and investment offices engage ESTRA to facilitate conversations, design protocols, and evaluate outcomes that their own structures cannot produce internally.